TAVI - New indications, techniques and devices - Part 2

Session comprising selected PCR London Valves 2023 Case submissions

Facilitators: R. Sarmento-Leite, R. Kharbanda

Speakers: M. Bellamoli, E. Messas, H. Ruge, G. Tang

Summary

Consult this session for a swift overview of evolving TAVI indications and techniques: gain insights into thirty-day outcomes with Evolut FX, stratified by heart team risk, witness the 12-month follow-up of the Valvosoft first-in-man study, uncover sizing considerations in bicuspid tapered aortic valves undergoing TAVI from the AD HOC registry, and more!

Presentations available when logged in:

Thirty-day outcomes after TAVR with Evolut FX stratified by heart team risk
12-month follow-up of the Valvosoft first-in-man study
Annular vs. supra-annular sizing in bicuspid tapered aortic valves undergoing TAVI: AD HOC registry
Comparison of bioprosthetic valve fracturing and "standard" post-dilatation in ViV-TAVR

Your free My PCR account will enable you to:

Become a PCR Companion
Access slide presentations from PCR Courses
Watch session videos and LIVE cases
Discuss cases with your peers
Submit and register for PCR Courses
Register for and view PCR Webinars
Read a selection of articles in EuroIntervention
And more…

TAVI - New indications, techniques and devices - Part 2

Session comprising selected PCR London Valves 2023 Case submissions

Log in or create account for free